From #TCT2024: 🎙️ This important discussion led by David Cohen covers the upcoming ARTIST Trial and the potential role and clinical impact of TAVR for patients with aortic regurgitation. 💡 https://lnkd.in/gQrYmFm7
JenaValve Technology, Inc.
Medical Equipment Manufacturing
Irvine, CA 10,174 followers
Aortic regurgitation is different. So is our valve.
About us
JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.
- Website
-
http://www.jenavalve.com
External link for JenaValve Technology, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Irvine, CA
- Type
- Privately Held
- Founded
- 2013
Locations
-
Primary
Get directions
4 Cromwell
Suite 100
Irvine, CA 92618, US
Employees at JenaValve Technology, Inc.
Updates
-
We are pleased to announce the start of the JENA-VAD Registry, to evaluate the performance of the Trilogy valve in LVAD patients with significant AR. 📄 Read the full press release to learn more: https://lnkd.in/gWDfCUBj
-
-
Don’t miss this State-of-the-Art Review on Non-Invasive Imaging for Aortic Regurgitation, recently published in the Journal of the American Society of Echocardiography 📢 Often times, patients with AR do not receive timely treatment — accurate assessment of AR severity by echo is an important first step! American Society of Echocardiography https://lnkd.in/ghQZzRqJ
-
Thank you for an exceptional #PCRLV! ✨ It was a pleasure connecting with all of you in London. We look forward to continuing this journey towards making #TAVI for aortic regurgitation a reality! #LondonValves2024
-
📣 #PCRLV Live Case Alert: TAVI for pure aortic regurgitation, tomorrow morning at 8:30, in the Main Arena. Don’t miss this live case from the University of Cologne! @MattiAdam_MD @ElmarWKuhn @CurioJonathan
-
Just ONE day to go! 🌟 The countdown to #PCRLV2024 is almost over, and we’re thrilled to see you in London 🇬🇧 tomorrow! Stop by the JenaValve booth (Booth #1) for an exclusive look at how we’re redefining possibilities with the world’s first dedicated #TAVI for aortic regurgitation. Don’t miss out—let’s innovate together!
-
Presented by Dr. Torsten Vahl at #TCT2024, 2-year follow-up data for the ALIGN-AR Trial showed the continued effectiveness of TAVR with the Trilogy valve for patients with severe and moderate-to-severe aortic regurgitation. See the full presentation here: https://lnkd.in/gDwYrtCZ
-
In the 2-year follow-up of the ALIGN-AR Trial, presented at #TCT2024, patients treated with the Trilogy valve showed sustained improvements in quality of life, with stable valve hemodynamics and no paravalvular regurgitation. 🌟
-
-
At #TCT2024, JenaValve presented encouraging 2-year data from our ALIGN-AR study, reinforcing the Trilogy THV System’s benefits for high-risk aortic regurgitation patients. We’re also excited to announce the launch of the ARTIST RCT, aiming to expand treatment options for AR! Read the full press release here: https://lnkd.in/gV5c-p56
-